SkyePharma reports Phase III Flutriform data

U.K.-based SkyePharma has completed a Phase III safety study of FlutiformTM, an asthma treatment. Results are consistent with the large safety database already accumulated on the individual constituents fluticasone and formoterol. In August, SkyPharma was dealt a setback when the FDA asked for more data before it would approve the drug. Three more studies are ongoing and the company expects submission of the NDA by the half of 2008.

- see the release for more

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.